Discover how advancing HER2 science is reshaping cancer care. By deepening understanding of tumor complexity and leveraging biomarker-driven approaches, we are enabling more precise therapies and driving innovation to improve outcomes for patients with HER2-expressing cancers and other areas of high unmet need.
Amal Melhem-Bertrandt, Vice President and Oncology Therapy Area Head, Research and Development, sheds light on gastroesophageal adenocarcinoma (GEA) and the significant impact it has on both life expectancy and quality of life for people living with this difficult-to-treat cancer.
Rob Iannone, Executive Vice President, Global Head of Research and Development and Chief Medical Officer, discusses the biology of HER2 expressing or amplified cancers and how identifying these HER2 amplifications can guide more targeted treatment approaches for patients.
Increased understanding around HER2 biology is helping to shape the future of cancer care. Amal Melhem-Bertrandt, Vice President and Oncology Therapy Area Head, Clinical Research and Development, discusses the importance of leveraging biomarker strategies for developing therapies that effectively target HER2-expressing cancers.
Chumi Khurana, Senior Vice President and Oncology Franchise Head, shares insights into our oncology strategy and ongoing commitment to advancing science in rare cancers across solid tumors, neuro-oncology and hematologic malignancies.
